ArticleJournal of diabetes science and technology2022
Building a Data-Driven Multiple Daily Insulin Therapy Model Using Smart Insulin Pens.
Article in Journal of diabetes science and technology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Article
- Glycemic outcomes with smart MDI system in type 1 diabetes: insights from a 12-Month retrospective study.Endocrine · 2026Observational
- Contributions of intermittently scanned continuous glucose monitoring frequency and bolus insulin dosing on time in range: Analysis of data from CGM and connected insulin pens.Diabetes, obesity & metabolism · 2025Article
- Safety of a Novel Continuous Glucose Monitoring-Informed Insulin Bolus Calculator Mobile Application for People With Type 1 or Type 2 Diabetes.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Connected Insulin Pens and Pen Caps: Expanding Diabetes Technology Access and Adoption.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Association Between Treatment Adherence and Continuous Glucose Monitoring Outcomes in People With Diabetes Using Smart Insulin Pens in a Real-World Setting.Diabetes care · 2024Article
- Shining the Spotlight on Multiple Daily Insulin Therapy: Real-World Evidence of the InPen Smart Insulin Pen.Diabetes technology & therapeutics · 2024Article
- Potential cost savings in the United States from a reduction in sensor-detected severe hypoglycemia among users of the InPen smart insulin pen system.Journal of managed care & specialty pharmacy · 2023Article
- A Review of Precision Insulin Management With Smart Insulin Pens: Opening Up the Digital Door to People on Insulin Injection Therapy.Journal of diabetes science and technology · 2023Review
- Pediatric Smart Insulin Pen Use: The Next Best Thing.Journal of diabetes science and technology · 2022Article
- Facilitators and Barriers to Smart Insulin Pen Use: A Mixed-Method Study of Multidisciplinary Stakeholders From Diabetes Teams in the United States.Clinical diabetes : a publication of the American Diabetes Association · 2022Article
- Digital Health Integration Assessment and Maturity of the United States Biopharmaceutical Industry: Forces Driving the Next Generation of Connected Autoinjectable Devices.JMIR mHealth and uHealth · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A growing suite of connected devices including Bluetooth or cellular-enabled glucose monitoring devices, smart insulin pens, pumps, fitness trackers, blood pressure, and heart rate and weight monitors present a golden opportunity to build a data-driven clinical practice model including remote monitoring capability and virtual care. This paper will discuss this approach using diabetes as a case study and smart insulin pens as a use case. As payment and practice approaches evolve, there is growing interest from both patients and their health care teams in virtual care made possible by remote monitoring capability. Here, we will define the category of smart insulin pens, describe the hallmarks of a data-driven practice model, and delineate the steps to take to incorporate remote monitoring capability with smart insulin pens into diabetes care for injection therapy patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.